Beneficial effects of Esketamine on Morphine preference reacquisition in male rats.
Neuroscience – May 07, 2025
Source: PubMed
Summary
Ketamine's medical cousin shows promise in preventing opioid relapse. In groundbreaking research, esketamine treatment helped rats resist returning to morphine-seeking behavior. Using a conditioned place preference test, researchers found that both daily and periodic esketamine doses effectively blocked the reestablishment of drug-seeking patterns, offering hope for addiction treatment.
Abstract
Addiction is a chronic condition that poses a serious public health challenge, particularly highlighted by the global opioid crisis involving drugs such as morphine (MORPH). One of the major obstacles in effective detoxification is the high relapse rate, with many individuals resuming drug use after withdrawal. Pharmacological treatments developed so far have generally shown limited efficacy in addressing substance use disorder. In this context, esketamine (ESK), the S-ketamine isomer, has been used in cases of treatment-resistant recurrent depression and depression with suicide risk. In our study, rats were treated with two doses of ESK every five days (acute - A-ESK) or daily (sub-chronic - SC-ESK) during MORPH-conditioned place preference (CPP) extinction. After 10 days, the animals were re-exposed to MORPH to assess preference reacquisition in the CPP paradigm. Our findings showed that both acute and sub-chronic ESK (A-ESK and SC-ESK) effectively prevented MORPH-CPP reestablishment. To our knowledge, this is the first experimental study to demonstrate the potential of ESK as a promising treatment for opioid abuse disorder. Clinical studies are needed to confirm its efficacy in human rehabilitation centers.